Understanding and managing interferon-α-related fatigue in patients with melanoma

Melanoma Research

Volumn 22, Issue 6, 2012, Pages 415-423

  Nashan, Dorothée ^a   Reuter, Katrin ^a   Mohr, Peter ^b   Agarwala, Sanjiv S ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Elbe Klinikum Buxtehude   (Germany)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

assessment tools; cancer related fatigue; depression; EORTC QLQ FA13 module; fatigue; interferon a; melanoma

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; METHYLPHENIDATE; MODAFINIL; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

BODY ACHE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RADIOTHERAPY; CHILL; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; COPING BEHAVIOR; DAILY LIFE ACTIVITY; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FATIGUE MODULE FA13; FEVER; FLU LIKE SYNDROME; FLUID INTAKE; HEALTH CARE ORGANIZATION; HUMAN; LOW DRUG DOSE; MEDLINE; MELANOMA; OVERALL SURVIVAL; PAIN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RECURRENCE FREE SURVIVAL; REVIEW; RISK FACTOR; SELF REPORT; SYMPTOM; SYSTEMATIC REVIEW;

FATIGUE; HUMANS; INTERFERON-ALPHA; MELANOMA; SKIN NEOPLASMS;

EID: 84869497033     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328358d98c     Document Type: Review

References (97)

1. Piper BF, Cella D. Cancer-related fatigue: definitions and clinical subtypes. J Natl Compr Canc Netw 2010; 8:958-966.
2. Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997; 34 (3 suppl 2):4-12.
3. Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000; 11:971-975.
4. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 2004;40-50.
5. Bruera E, Yennurajalingam S. Challenge of managing cancer-related fatigue. J Clin Oncol 2010; 28:3671-3672.
6. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009; 7:1-21.
7. Djä rv T, Lagergren P. Six-month postoperative quality of life predicts longterm survival after oesophageal cancer surgery. Eur J Cancer 2011; 47:530-535.
8. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5:353-360.
9. Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 2003; 98: 1786-1801.
10. Flechtner H, Bottomley A. Fatigue and quality of life: lessons from the real world. Oncologist 2003; 8 (suppl 1):5-9.
11. Butt Z, Rosenbloom SK, Abernethy AP, Beaumont JL, Paul D, Hampton D, et al. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw 2008; 6:448-455.
12. Brown LF, Kroenke K. Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 2009; 50:440-447.
13. Seyidova-Khoshknabi D, Davis MP, Walsh D. Review article: a systematic review of cancer-related fatigue measurement questionnaires. Am J Hosp Palliat Care 2011; 28:119-129.
14. Kirsh KL, Passik S, Holtsclaw E, Donaghy K, Theobald D. I get tired for no reason: a single item screening for cancer-related fatigue. J Pain Symptom Manage 2001; 22:931-937.
15. National Comprehensive Cancer Network. NCCN guidelines for supportive care. Cancer-related fatigue. Available at: http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp#site [Accessed 30 November 2011].
16. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34:13-19.
17. Smets EM, Garssen B, Schuster-Uitterhoeve AL, de Haes JC. Fatigue in cancer patients. Br J Cancer 1993; 68:220-224.
18. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39:315-325.
19. Donovan KA, Jacobsen PB. The Fatigue Symptom Inventory: a systematic review of its psychometric properties. Support Care Cancer 2010; 19: 169-185.
20. European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Study Groups. EORTC QOL module for cancer related fatigue: EORTC QLQ-FA13 Available at: http://groups.eortc.be/qol/cancerrelated-fatigue-eortc- qlq-fa13. [Accessed 30 November 2011].
21. Weis J, Arraras JI, Conroy T, Efficace F, Fleissner C, Gö rög A, et al. Development of an EORTC quality of life phase III module measuring cancer-related fatigue (EORTC QLQ-FA13). Psychooncology 2012 [Epub ahead of print].
22. European Organisation for Research and Treatment of Cancer (EORTC) QOL. EORTC-QLQ-C30 (version 3). Available at: http://groups.eortc. be/qol/eortc-qlq-c30 [Accessed 30 November 2011].
23. Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001; 19:3385-3391.
24. Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and management. Oncologist 1999; 4:1-10.
25. Reuter K, Hä rter M. The concepts of fatigue and depression in cancer. Eur J Cancer Care (Engl) 2004; 13:127-134.
26. Jacobsen PB, Donovan KA, Weitzner MA. Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsychiatry 2003; 8:229-240.
27. Visser MR, Smets EM. Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer 1998; 6:101-108.
28. Andrews PL, Morrow GR, Hickok JT. Mechanisms and models of fatigue associated with cancer and its treatment: evidence of pre-clinical and clinical studies. In: Armes J, Krishnasamy M, Higginson I, editors. Fatigue in cancer. Oxford: Oxford University Press; 2004. pp. 51-87.
29. Barsevick AM, Dudley WN, Beck SL. Cancer-related fatigue, depressive symptoms, and functional status: a mediation model. Nurs Res 2006; 55:366-372.
30. Stepanski EJ,Walker MS, Schwartzberg LS, Blakely LJ, Ong JC, Houts AC. The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. J Clin Sleep Med 2009; 5:132-136.
31. Beck AT, Rush J, Shaw BF, Emery G, Hautzinger M. Kognitive therapie der depression. Basel: Beltz Verlag; 1994.
32. Weissman MM, Markowitz JC, Klerman GL. Comprehensive guide to interpersonal psychotherapy. New York: Basic Books; 2000.
33. Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PL, Flynn PJ, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003; 21:4635-4641.
34. Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005; 89:243-249.
35. Arnold LM. Understanding fatigue in major depressive disorder and other medical disorders. Psychosomatics 2008; 49:185-190.
36. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, et al. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res 2008; 18:152-160.
37. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46:270-283.
38. Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann R-D, et al. Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 2008; 6 (suppl 1):S9-S14.
39. National Comprehensive Cancer Network. NCCN guidelines for treatment of cancer by site: melanoma. Available at: http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp#site [Accessed 30 November 2011].
40. Né grier S, Saiag P, Guillot B, Verola O, Avril MF, Bailly C, et al. Clinical practice guideline: 2005 update of recommendations for the management of patients with cutaneous melanoma without distant metastases (summary report). Bull Cancer 2006; 93:371-384.
41. Bergenmar M, Nilsson B, Hansson J, Brandberg Y. Anxiety and depressive symptoms measured by the Hospital Anxiety and Depression Scale as predictors of time to recurrence in localized cutaneous melanoma. Acta Oncol 2004; 43:161-168.
42. Newton-Bishop JA, Nolan C, Turner F, McCabe M, Boxer C, Thomas JM, et al. A quality-of-life study in high-risk (thickness Z or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc 2004; 9:152-159.
43. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372:117-126.
44. Heinze S, Egberts F, Rö tzer S, Volkenandt M, Tilgen W, Linse R, et al. Depressive mood changes and psychiatric symptoms during 12-month lowdose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial. J Immunother 2010; 33:106-114.
45. Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:731-746.
46. Schaefer M, Schmidt F, Horn M, Schmid-Wendtner MH, Volkenandt M. Depression during treatment with interferon alpha. Psychosomatics 2004; 45:176.
47. Trask PC, Paterson AG, Esper P, Pau J, Redman B. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology 2004; 13:526-536.
48. Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009; 27:2916-2923.
49. Agarwala SS, di Pietro A, Flaherty KT, Garbe C, Grob JJ, Kashani-Sabet M, et al. Meeting report from the third global workshop on melanoma. Pigment Cell Melanoma Res 2010; 23:e1-e7.
50. Butt Z, Rao AV, Lai JS, Abernethy AP, Rosenbloom SK, Cella D. Ageassociated differences in fatigue among patients with cancer. J Pain Symptom Manage 2010; 40:217-223.
51. Rao D, Debb S, Blitz D, Choi SW, Cella D. Racial/ethnic differences in the health-related quality of life of cancer patients. J Pain Symptom Manage 2008; 36:488-496.
52. Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, et al. The relationship between overall quality of life and its subdimensions was influenced by culture: analysis of an international database. J Clin Epidemiol 2008; 61:788-795.
53. Rataj D, Jankowiak B, Krajewska-Kułak E, Van Damme-Ostapowicz K, Nowecki ZI, Rutkowski P, et al. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients. Cancer Nurs 2005; 28:172-178.
54. Ziefle S, Egberts F, Heinze S, Volkenandt M, Schmid-Wendtner M, Tilgen W, et al. Health-related quality of life before and during adjuvant interferon-alpha treatment for patients with malignant melanoma (DeCOG-trial). J Immunother 2011; 34:403-408.
55. Schlesinger-Raab A, Schubert-Fritschle G, Hein R, Stolz W, Volkenandt M, Hö lzel D, et al. Quality of life in localised malignant melanoma. Ann Oncol 2010; 21:2428-2435.
56. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Available at: http://www.cochrane-handbook.org/[Accessed 29 February 2012].
57. The Cochrane Collaboration. The Cochrane Library. Available at: http://www.cochranelibrary.com [Accessed 29 February 2012].
58. Wolters and Kluwer. Wolters Kluwer Health-OvidSP. Available at: http://ovidsp.ovid.com [Accessed 29 February 2012].
59. Schwartz AL, Thompson JA, Masood N, Schwartz JA. Interferon-induced fatigue in patients with malignant melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002; 29:85-90.
60. Caraceni A, Gangeri L, Martini C, Belli F, Brunelli C, Baldini M, et al. Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. Cancer 1998; 83:482-489.
61. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4:234-243.
62. Hauschild A, Weichenthal M, Rass K, Linse R, Ulrich J, Stadler R, et al. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph nodenegative melanoma. J Clin Oncol 2009; 20:3496-3502.
63. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20:3703-3718.
64. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004; 56:819-824.
65. Gogas H, Bafaloukos D, Ioannovich J, Skarlos D, Polyzos A, Fountzilas G, et al. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year-a Hellenic Cooperative Oncology Group Study. Anticancer Res 2004; 24:1947-1952.
66. Chiarion-Sileni V, Del Bianco P, Romanini A, Guida M, Paccagnella A, Dalla Palma M, et al. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI-Mel.A.) [ISRCTN75125874]. BMC Cancer 2006; 6:44.
67. Dummer R, Garbe C, Thompson JA, Eggermont AM, Yoo K, Maier T, et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006; 24: 1188-1194.
68. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996; 14:2666-2673.
69. Brandberg Y, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, et al. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b. Eur J Cancer 2012; 48:2012-2019.
70. Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol 2011; 12:144-152.
71. Dy SM, Lorenz KA, Naeim A, Sanati H,Walling A, Asch SM. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 2008; 26:3886-3895.
72. Stone PC, Minton O. Cancer-related fatigue. Eur J Cancer 2008; 44: 1097-1104.
73. Fancher TL, Kravitz RL. In the clinic. Depression. Ann Intern Med 2010; 152:ITC5-1-ITC5-16, quiz ITC55-16.
74. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004; 15:979-986.
75. Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 2004; 91:822-828.
76. Cella D, Viswanathan HN, Hays RD, Mendoza TR, Stein KD, Pasta DJ, et al. Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. Cancer 2008; 113:1480-1488.
77. Kilbridge KL, Weeks JC, Sober AJ, Haluska FG, Slingluff CL, Atkins MB, et al. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 2001; 19:812-823.
78. Levesque N, Mitchinson K, Lawrie D, Fedorak L, Macdonald D, Normand C, et al. Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma. Curr Oncol 2008; 15:36-41.
79. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, et al. Postsurgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366:1189-1196.
80. Hancock BW,Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 1:53-61.
81. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19:2370-2380.
82. Escalante CP, Kallen MA, Valdres RU, Morrow PK, Manzullo EF. Outcomes of a cancer-related fatigue clinic in a comprehensive cancer center. J Pain Symptom Manage 2010; 39:691-701.
83. Breitbart WS, Alici Y. Psycho-oncology. Harv Rev Psychiatry 2009; 17:361-376.
84. Drapkin R, Barolo JL, Blower PR. Effect of granisetron on performance status during high-dose interferon therapy. Oncology 1999; 57:303-305.
85. Fatigue. Available at: www.melanoma.com/fatigue.html [Accessed 30 November 2011].
86. National Institutes of Health, National Cancer Institute. Fatigue (PDQs): overview. Available at: www.cancer.gov/cancertopics/pdq/supportivecare/fatigue/ HealthProfessional [Accessed 30 November 2011].
87. Bradt J, Dileo C, Grocke D, Magill L. Music interventions for improving psychological and physical outcomes in cancer patients. Cochrane Database Syst Rev 2011;CD006911.
88. Keogh JW, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review. J Pain Symptom Manage 2012; 43:96-110.
89. Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 2010; 4:87-100.
90. Schmitz KH, Holtzman J, Courneya KS, Masse LC, Duval S, Kane R. Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2005; 14:1588-1595.
91. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 2010;CD006704.
92. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 1998; 12:369-377.
93. Campos MP, Hassan BJ, Riechelmann R, Del Giglio A. Cancer-related fatigue: a practical review. Ann Oncol 2011; 22:1273-1279.
94. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dreno B, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112:982-994.
95. Piper BF, Borneman T, Sun VC, Koczywas M, Uman G, Ferrell B, et al. Cancer-related fatigue: role of oncology nurses in translating National Comprehensive Cancer Network assessment guidelines into practice. Clin J Oncol Nurs 2008; 12 (5 suppl):37-47.
96. Dixon S, Walters SJ, Turner L, Hancock BW. Quality of life and costeffectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 2006; 94:492-498.
97. Mohr P, Hauschild A, Enk A, Trefzer U, Raas K, Grabbe S, et al. Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: an interim analysis of a randomized phase III study (NCT00226408). 44th ASCO Annual Meeting; 30 May to 3 June 2008; Chicago, IL.